Drugs / rhEPO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01441427 | Jan 2010 → Apr 2011 | necrotizing enterocolitis | Ain Shams University | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 0 | NCT03093506 Comparator | Sep → Dec 2011 | — | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06854276 Comparator | Mar 2025 → Dec 2027 expected | aregenerative anemia | Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT01977482 Comparator | Nov 2013 → Feb 2015 | anemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01587924 Comparator | May 2012 → May 2013 | anemia | GlaxoSmithKline | Completed | No outcome recorded |
| — | NCT00939978 Comparator | Apr 2009 → Jun 2010 | cardiac valvular defect | Yonsei University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhEPO | “enteral recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human erythropoietin (rhEPO) in preventing feeding intolerance” PMID 25155966 ↗ Aug 2014 |
| Known as | recombinant human erythropoietin | “High-dose recombinant human erythropoietin (rhEpo) has been shown to improve cognitive performance in both healthy volunteers and in patients suffering from diseases affecting...” PMID 28874242 ↗ Sep 20172“stable dose of recombinant human erythropoietin (rhEPO)” NCT01977482 ↗ “recombinant human erythropoietin(rhEPO)” NCT00939978 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human erythropoietin(rhEPO)” NCT00939978 ↗ |
| Route | Other | “administered by an orogastric tube” NCT01441427 ↗ |